

# Eluvia DES for the Patients with Femoropopliteal Artery Lesions.

NCT05522218

---

|                   |                                                  |
|-------------------|--------------------------------------------------|
| <b>Status</b>     | RECRUITING                                       |
| <b>Sponsor</b>    | First Affiliated Hospital of Zhejiang University |
| <b>Enrollment</b> | 400 participants                                 |

## Key Eligibility Criteria

---

### Inclusion (4)

- Rutherford Stage 2-5.
- At least 90% stenosis or occlusion of the femoropopliteal artery.
- Eluvia stents are used for target lesions.
- Agree and sign the informed consent form

### Exclusion (5)

- Life expectancy is less than 1 year.
- Those with severe infection and gangrene of the limbs or those with tissue defects beyond the plane of the toes (ie major tissue loss), who may undergo major amputation even if the blood vessels are opened.
- Patients and their families are reluctant to join the observational study, or have difficulty in communication and are unable to assess the quality of life.
- Patients with in-stent restenosis of the femoral popliteal artery.
- Patients with acute arterial thrombosis.

## Locations (1 total)

---

First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China